What can I do to protect my bones whilst taking GLP-1 treatment
Semaglutide and other GLP-1 agonistsmedications that bind to GLP-1 receptors and mimic their effectsare currently used as treatments for diabetes and obesity
However, quality of life considerations remain paramount, and alternative therapeutic options should be discussed if side effects significantly impair daily functioning despite comprehensive management strategies
67.1% (593/884) of patients prescribed DAAs since July 2023 have initiated DAAs
AOM tirzepatide, in contrast, began lower at 0.3% in January 2024, but grew rapidly, surpassing prescribing rates of AOM semaglutide by late 2024
To date, Ro has helped over 2 million people understand their benefits coverage to get the best medication for them